NEW YORK – Tempus AI announced Thursday that it has partnered with the nonprofit Institute for Follicular Lymphoma Innovation to accelerate the development of targeted therapies for follicular lymphoma (FL).
The partners will develop and make available a real-world multimodal FL data library in Tempus' data analytics platform Lens that researchers can use to accelerate the development of FL treatments. The collaboration will initially focus on prospectively generating multimodal FL data through a Tempus-sponsored study, particularly for patients who experience disease progression within two years of treatment, Tempus said in a statement.
The FL data library "has the potential to improve researchers' understanding of the disease's biology," and providing access to the data "supports their work in uncovering critical insights into the heterogeneity of FL, which may lead to the development of more targeted precision medicines," Tempus said.
Tempus' Lens platform is a cloud-based data and analytics platform that is intended to provide researchers at biotech and pharma companies with on-demand access to de-identified clinical and molecular datasets, as well as artificial intelligence-based analytical tools, to accelerate drug discovery and development.
"Together, we aim to create a robust, de-identified FL database, accelerating research and drug development to ultimately find a cure for the FL patient community," IFLI Managing Director David McCullagh said in a statement. "We believe Tempus is uniquely positioned to develop this comprehensive FL database, making it accessible to professionals in the field to combat this disease effectively."
The IFLI is a nonprofit organization dedicated to accelerating the development of innovative treatment options for FL patients by supporting research and technology to lead to the development and commercialization of novel therapeutics and biomarkers.